Hear about the unprecedented overall survival and additional outcomes for patients with 1L ESCC and PD-L1 scores ≥1%1
Watch this video to learn about the clinical trial results with TEVIMBRA + chemotherapy vs placebo + chemotherapy
1L, first line; ESCC, esophageal squamous cell carcinoma; PD-L1, programmed death ligand 1.
Reference: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026.